Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...

Recent research takes aim at the a variant in gene SCN1B, which causes a severe form of developmental epileptic encephalopathy.

Dravet syndrome is a severe genetic disorder marked by frequent, severe seizures and cognitive and behavioral impairments, with an estimated 38,000 affected individuals in the U.S., UK, EU-4, and ...

Biogen ( NASDAQ: BIIB) and Stoke Therapeutics ( NASDAQ: STOK) said on Tuesday they are collaborating to develop and ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of ...

Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.

On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories outside the United ...